

Recombinant Human CD80/B7-1 Protein

Catalog No. PKSH031476

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

| | |
|------------------------------------|---|
| Synonyms | CD80;Activation B7-1 antigen;B7;BB1;CD28LG1;CD28LGB7-1 antigen;T-lymphocyte activation antigen CD80;B7-1;B7.1;CD28LG;LAB7 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Asn 242 |
| Accession | NP_005182.1 |
| Calculated Molecular Weight | 25.5 kDa |
| Tag | None |
| Bioactivity | Not validated for activity |

Properties

| | |
|-----------------------|---|
| Purity | > 85 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per µg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |

Data



> 85 % as determined by reducing SDS-PAGE.

Background

The B-lymphocyte activation antigen B7-1 (referred to as B7); also known as CD80; is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells;

For Research Use Only

macrophages and dendritic cells. As costimulatory ligands; B7-1 which exists predominantly as dimer and the related protein B7-2; interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells; and thus constitute one of the dominant pathways that regulate T cell activation and tolerance; cytokine production; and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.